Trial Information
Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Inclusion Criteria:
- 18 years or older
- Stage IIIb, metastatic, or recurrent NSCLC patients who have received one prior
platinum-based chemotherapy regimen
- ECOG performance status score of 0 or 1
Exclusion Criteria:
- Laboratory values indicating inadequate function of bone marrow, liver, or kidneys
- Symptomatic or uncontrolled brain metastases
- Evidence of meningeal metastasis
- > 1 prior regimen (not counting adjuvant or neo-adjuvant cytotoxic chemotherapy if
completed > 12 months prior to regiment)
- Medical condition that would increase risk if treated with motexafin gadolinium or
impair ability to complete study procedures and assessments
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
6 month progression free survival
Outcome Description:
proportion of patients who are still alive and who have not progressed clinically or radiographically 6 months after receiving their first dose of MGd.
Outcome Time Frame:
up to 2 years
Safety Issue:
No
Principal Investigator
Martin Edelman, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Maryland, Greenbaum Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
PCYC-0228
NCT ID:
NCT00365183
Start Date:
June 2006
Completion Date:
June 2008
Related Keywords:
- Non-Small Cell Lung Carcinoma
- Non Small Cell Lung Cancer
- Lung Cancer
- Metastatic Lung Cancer
- Inoperable Lung Cancer
- Advanced Lung Cancer
- Large Cell Lung Cancer
- Adenocarcinoma, lung
- Squamous Cell Carcinoma, lung
- Squamous Cell Lung Cancer
- Large Cell Carcinoma, lung
- Cancer of the Lung
- Carcinoma
- Bronchogenic
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|
Hinsdale, Illinois 60521 |
|
Alexandria, Minnesota 56308 |
|
Fountain Valley, California 92708 |
|
Columbia, Missouri 65203 |
|
Albany, New York 12208 |
|
Cleveland, Ohio 44195 |
|
Seattle, Washington 98195 |
|
Albuquerque, New Mexico 87131-5636 |
|
Baltimore, Maryland 21287 |